High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
FEATURE The artificial-intelligence rally may be grinding to a halt. Technology stocks were getting hit hard on Thursday after mediocre revenue guidance from Broadcom caused investors to question how fast AI demand will accelerate.
Investing.com -- Bank of America upgraded UnitedHealth Group to Buy from Neutral and raised its price target to $450 from $420 per share in a note on Thursday, citing improving medical cost trends and a favorable setup heading into second-quarter earnings, analyst Kevin Fischbeck said.
UnitedHealth, The Cigna, Humana, Centene and Molina have been highlighted in this Industry Outlook article.
FTSE 100 up 8 points to 10,341 Oil prices soften on Israel-Lebanon ceasefire CMC Markets nears five-year high on results 2.56pm: Toddlers' picnic on Wall Street As expected, Wall Street has opened like a toddlers' picnic, with everyone heading off in different...
Aging demographics, sound Medicare premiums, digital healthcare adoption and increased M&A activity are likely to drive the performance of the Zacks Medical-HMO industry players. UNH, CI, HUM, CNC and MOH are poised to benefit from favorable industry prospects.
The Mairs & Power, an investment firm, released the first-quarter 2026 investor letter for the “Mairs & Power Balanced Fund.” A copy of the letter can be downloaded here. The fund returned -1.77% in the first quarter of 2026, outperforming its benchmark composite index decline of -2.68% as strong stock selection and exposure to Utilities […]
Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health.
While Cigna has lagged behind the broader healthcare sector over the past year, Wall Street analysts remain highly bullish about the stock’s prospects.
Massachusetts has filed a lawsuit against UnitedHealth Group, alleging the company exaggerated illness severity for Medicaid patients to obtain higher payments. The case focuses on claimed inflation of patient risk scores within the state’s Medicaid program and UnitedHealth has denied any wrongdoing. The lawsuit introduces additional legal and reputational questions for UnitedHealth Group that go beyond routine operational updates. UnitedHealth Group (NYSE:UNH) is facing this legal...
Growth, not yield, is the deciding factor.
UnitedHealth Group (NYSE:UNH) is a stock worth owning for decades because the aging of America makes its cash flows close to legislatively guaranteed, and almost nothing in the public markets matches the combination of scale, integration, and shareholder return discipline this company has built around that demographic certainty. Pillar One: A Business Built to Last ... Forget Market Volatility: This Cash-Flow Machine Is a Once-in-a-Generation Buy and Never Sell Stock
UNH plans to eliminate nearly two-thirds of pediatric prior authorizations by year-end, aiming to speed care access and reduce provider paperwork.
ORCL, MU and HPP led standout gains as Zacks highlighted top-performing portfolios amid volatile markets and inflation worries.
Elevance Health has underperformed the Health Care sector over the past year, but analysts are moderately optimistic about the stock’s prospects.
The state claims UnitedHealthcare inflated the sickness of seniors enrolled in MassHealth managed care plans to reap at least $100 million in improper payments.
Oscar Health’s tech-driven growth contrasts with UnitedHealth’s massive scale and diversified revenue.
Investing.com -- Massachusetts filed a lawsuit on Friday against a UnitedHealth insurance unit, alleging the company defrauded the state's Medicaid program of more than $100 million by inflating the severity of illnesses among older patients.
The Dow Jones (^DJI) is packed with iconic businesses that have built strong brands and durable market positions. A select few continue to thrive, delivering solid returns and proving their resilience in an evolving market.
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The insurer is removing nearly two-thirds of approval requirements for patients under 18.
Auxier Asset Management, an investment advisory firm, released its first quarter 2026 investor letter. A copy of the letter is available to download here. Following a robust start to the year, the market was impacted by the Strait of Hormuz crisis. Concerns over AI disruption, excessive stock-based compensation, and high valuations caused the technology sector […]
UnitedHealth Group plans to stop requiring doctors to get approvals for an array of pediatric procedures, tests and services, further cutting back on a process that has long been detested by physicians and patients.
Berkshire Hathaway has exited its position in UnitedHealth Group, selling its remaining stake in NYSE:UNH. The sale comes as UnitedHealth continues to work through regulatory issues and implements changes such as Optum Rx's transparent pharmacy benefit model. Berkshire's exit is being watched closely as a potential signal of shifting institutional sentiment toward UnitedHealth's risk and return profile. UnitedHealth Group, trading at around $382.53, sits at the center of US managed care and...
As UnitedHealth Group has considerably outperformed its sector peers recently, analysts remain highly optimistic about the stock’s prospects.
MOH's Medicaid focus, dual-eligible expansion and stronger share gains make it stand out against UNH in managed care.
Centene (CNC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
